Lipid-Lowering Agents - Mexico

Mexico

The Lipid-Lowering Agents market in Mexico is projected to generate a revenue of €47.38m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 0.01%, leading to a market volume of €47.40m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue in the Lipid-Lowering Agents market, reaching €4,137.00m in 2024.
In Mexico, the market for lipid-lowering agents is experiencing a surge in demand due to the high prevalence of cardiovascular diseases in the country.

Key regions: Europe, Brazil, France, Australia, Germany

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Lipid-Lowering Agents in Mexico has been on the rise in recent years, driven by factors such as an aging population, sedentary lifestyles, and unhealthy dietary habits.

Customer preferences: Mexican consumers are increasingly aware of the health risks associated with high cholesterol levels and are turning to Lipid-Lowering Agents as a preventative measure. This trend is particularly evident among the middle-aged and elderly population, who are more likely to suffer from cardiovascular diseases.

Trends in the market: The Lipid-Lowering Agents market in Mexico is dominated by statins, which account for the majority of sales. However, there is a growing demand for alternative treatments such as PCSK9 inhibitors and ezetimibe. This trend is driven by the increasing prevalence of statin intolerance among patients, as well as the high cost of these drugs.

Local special circumstances: The Mexican government has implemented a number of initiatives to promote healthy lifestyles and combat obesity, which is a major risk factor for cardiovascular disease. These include public education campaigns, taxes on sugary drinks, and regulations on food labeling. These efforts are likely to increase demand for Lipid-Lowering Agents in the long term, as consumers become more health-conscious.

Underlying macroeconomic factors: Mexico's healthcare system is undergoing significant reforms, with a focus on increasing access to healthcare services and improving the quality of care. This is likely to boost demand for Lipid-Lowering Agents as more patients are diagnosed and treated for cardiovascular disease. Additionally, Mexico's aging population is expected to drive demand for these drugs in the coming years, as the risk of cardiovascular disease increases with age.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.